Please login to the form below

Cancer Drugs Fund

This page shows the latest Cancer Drugs Fund news and features for those working in and with pharma, biotech and healthcare.

NICE launches consultation on its methods of drug evaluation

Public consultation launched on Friday 6 November. The UK’s National Institute of Health and Care Excellence is finally set to review its methods of evaluation for drugs, medical devices and ... In addition, new cancer treatments can be approved via

Latest news

NICE recommends Roche’s Polivy for B-cell lymphoma

Earlier this year, NICE initially rejected the new cancer drug, citing a lack of long-term evidence as the reason for the rejection. ... NICE said that the cost-effectiveness of the Polivy combination treatment was ‘very uncertain’, meaning it
NICE recommends Merck/Pfizer’s PD-L1 inhibitor Bavencio for kidney cancer

as a treatment for kidney cancer for use within the Cancer Drugs Fund. ... number of cancer immunotherapies including Merck &Co’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo (nivolumab).
Celgene’s Revlimid scores NICE approval in follicular lymphoma

However, Revlimid will become immediately accessible with interim funding provided via the Cancer Drugs Fund, until the final guidance is published and the funding switches to routine commissioning budgets. ... Lenalidomide is a new type of targeted
NICE turns down Keytruda/Inlyta combo for kidney cancer

The agency also says it can’t recommend the regimen for coverage by the Cancer Drugs Fund – which covers the cost of cancer drugs until confirmatory data is available – because “uncertainties ... Opdivo/Yervoy reduced the risk of death by 37% in
NICE recommends Ibrance and Lynparza, rejects Keytruda and Xospata

Ibrance. Pfizer received a positive answer from the cost-effectiveness watchdog, with NICE approving its breast cancer drug Ibrance (palbociclib) for use on the Cancer Drugs Fund. ... We are pleased that the company has agreed a managed access agreement

More from news
Approximately 53 fully matching, plus 122 partially matching documents found.

Latest Intelligence

30 Women Leaders in UK Healthcare

A very notable victory has just been announced, with Keytruda becoming the first of the groundbreaking immunotherapy drugs to exit the Cancer Drugs Fund and secure NICE approval for first-line ... Current projects include developing antibodies for use as
Uncertainty, austerity and Brexit

Companies have seen repeated attempts by the Government and NHS England to prevent patients from accessing new medicines, from the controversial reforms to the Cancer Drugs Fund to the ‘run rate’
Opening up market access

In this PME market access supplement we look at the direction of travel in France and Germany and there’s an introduction to the UK’s new-look Cancer Drugs Fund.
Stepping up to payer-driven market access

products. In the UK, for instance, NICE now regulates access to the Cancer Drugs Fund, and products will need to meet NICE thresholds in order to be reimbursed.
The price is right?

Health stakeholders should focus not on the cost of drugs but on the value they provide. ... Proposed changes to the Cancer Drugs Fund in England include provision for access at a provisional price that is considered potentially cost-effective.

More from intelligence
Approximately 2 fully matching, plus 12 partially matching documents found.

Latest appointments

New health ministers and re-appointments after reshuffle

Freeman's role is also tied into the Department for Business, Innovation and Skills and includes expanded responsibility for the Cancer Drugs Fund, NICE and MHRA, research and development, issues around ... the uptake of new drugs and med tech, and the
Celgene names general manager for UK and Ireland

This is even more pertinent with the recent changes to the Cancer Drugs Fund, which I strongly hope will enable patients with myeloma and metastatic pancreatic cancer to continue to be

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Let's be ambitious for patients and life sciences investment in Global Britain

From the Cancer Drugs Fund to the promised Innovation Drugs Fund, initiatives have been created as technical ‘work-arounds’ for NICE and for an HTA system that has not kept pace
Delivering true value: what does it mean for KAM in cancer care?

So, it is essential to understand the roles of local organisations, such as Primary Care Networks (PCNs) and Cancer Alliances and Rapid Diagnostic Centres (RDCs). ... of commissioning alongside the Cancer Drugs Fund and the dust has not settled yet with
How to make the most of online communities

topical healthcare issues including NICE, the Cancer Drugs Fund, biosimilars, the impact of Digital on pharma and the NHS in general.

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Medical Editor: Competitive

Account Director – Creative Healthcare Communications: Competative

Healthcare Lead Copywriter: Competitive

Account Manager Healthcare / Pharmaceutical Sector: Negotiable Salary

Healthcare Account Director: Competitive

Healthcare Senior Account Manager: Competitive

Sales Director, Healthcare communications agency, London/ SE UK: Six figure salary

PMHub

Add my company

Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

Sourcing R&D innovation: why pharma companies need to evolve their business models: Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?: 2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
The search for effective drug treatments for COVID-19: PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...